Format

Send to

Choose Destination
Br J Ophthalmol. 2018 Nov;102(11):1497-1503. doi: 10.1136/bjophthalmol-2017-311544. Epub 2018 Jul 4.

Preservatives in glaucoma medication.

Author information

1
Department of Ophthalmology, Eerste River and Groote Schuur Hospitals, University of Cape Town, Cape Town, South Africa.
2
Department of Ophthalmology, Bradford Royal Infirmary, Bradford, UK.
3
Department of Ophthalmology, St Thomas' Hospital, London, UK shenglim@gmail.com.

Abstract

Preservatives continue to be in widespread use in ophthalmic medications due to the convenience they provide, regulatory requirements and the higher cost of alternatives. Benzalkonium chloride (BAK) remains the most commonly used preservative but there is a trend towards the use of preservative-free (PF) drops for glaucoma, although at a higher price. An extensive body of literature explores BAK toxicity on ocular structures in animal and laboratory studies (in vitro and in vivo). Non-randomised controlled studies have provided some supporting evidence of its toxicity in patients, especially in those with pre-existing ocular surface disease (OSD) or on multiple medications. However, there have been very few randomised controlled trials that compare the same medication with and without BAK preservative. Several of these trials have never been published in any peer reviewed journals. Notwithstanding, those that have been published, have not demonstrated any clear benefits of the BAK-free formulations. Short duration and exclusion of those with OSD are limitations of these studies. There is a lack of evidence of clinically significant harm from a small number of BAK preserved drops in patients without OSD. This means that generally more expensive PF glaucoma medications should only be recommended for those on poly pharmacy or those with OSD but are not necessarily required for all patients.

KEYWORDS:

BAK; benzalkonium chloride; glaucoma; ocular surface disease (OSD).; preservatives

PMID:
29973365
PMCID:
PMC6241623
DOI:
10.1136/bjophthalmol-2017-311544
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Competing interests: KSL has received grant from the Thea pharmaceuticals and travel support and lecture/consultancy fees from Allergan, Alcon, MSD and Thea. He is also an investigator in prospective randomised controlled trials using preservative-free glaucoma medications funded by the Allergan, Thea and Santen. DWS does not have any competing interest. PA has received educational grants and lecture fees from Thea pharmaceutical.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center